0000000000238563

AUTHOR

A Azzolina

showing 9 related works from this author

Gene expression profiling of human liver cancer cells following celecoxib tretment

2010

Celecoxibglobal gene expression analysisHCCCOX-2microarray
researchProduct

Altered gene expression profiles in liver cancer cells upon sorafenib treatment

2010

global gene expression analysisSorafenibHCCmicroarray
researchProduct

Development of nimesulide loaded solid lipid nanoparticles.

2009

Settore CHIM/09 - Farmaceutico Tecnologico ApplicativoSOLID LIPID NANOPARTICLES DRUG DELIVERY
researchProduct

Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells

2014

Background: In hepatocellular carcinoma (HCC), different signaling pathways are de-regulated, and among them, the expression of the epidermal growth factor receptor (EGFR). Tyrphostin AG-1478 is a lipophilic low molecular weight inhibitor of EGFR, preferentially acting on liver tumor cells. In order to overcome its poor drug solubility and thus improving its anticancer activity, it was entrapped into nanostructured lipid carriers (NLC) by using safe ingredients for parenteral delivery. Results: Nanostructured lipid carriers (NLC) carrying tyrphostin AG-1478 were prepared by using the nanoprecipitation method and different matrix compositions. The best system in terms of mean size, PDI, zeta…

DrugCarcinoma HepatocellularHepatocellular carcinomamedia_common.quotation_subjectBiomedical EngineeringMedicine (miscellaneous)Pharmaceutical ScienceAntineoplastic AgentsBioengineeringPharmacologyApplied Microbiology and BiotechnologyCell Line TumormedicineHumansEpidermal growth factor receptorNanostructured lipid carriers Tyrphostin AG-1478 Drug release Hepatocellular carcinoma EGFR inhibitor.media_commonEGFR inhibitorsDrug CarriersNanostructured lipid carriersbiologyChemistryResearchLiver NeoplasmsCorrectionDrug releaseTyrphostinsmedicine.diseaseLipidsTyrphostin AG-1478Molecular medicineIn vitroNanostructuresErbB ReceptorsEGFR inhibitorLiverSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoHepatocellular carcinomaDrug deliveryQuinazolinesbiology.proteinMolecular MedicineDrug carrier
researchProduct

ENTRAPMENT OF TYRPHOSTIN AG 14-78 INTO LIPID NANOPARTICLES IMPROVES ITS ANTITUMOR ACTIVITY AGAINST HUMAN HEPATOCARCINOMA CELLS

2014

SOLID LIPID NANOPARTICLES CANCER
researchProduct

The novel NF-kB inhibitor DHMEQ suppresses the growth of human hepatic cancer cells though redox-dependent signaling

2009

Cancer cells hepatocellular carcinoma NF-kB inhibitorSettore MED/06 - Oncologia Medica
researchProduct

Encapsulation of sorafenib into lipid nanoparticles improves its antitumor activity.

2013

Settore CHIM/09 - Farmaceutico Tecnologico ApplicativoSOLID LIPID NANOPARTICLES SORAFENIB
researchProduct

Effects of kind and amount of surfactants on physical-chemical properties of cationic solid lipid nanoparticles (SLN) for the treatment of hepatocell…

2014

Settore CHIM/09 - Farmaceutico Tecnologico ApplicativoSOLID LIPID NANOPARTICLES HEPATOCELLULAR CARCINOMA
researchProduct

Lipid nanocarrier for the treatment of hepatocellular carcinoma

2013

Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and the third most frequent cause of cancer-related death. Unlike most solid tumors the incidence and mortality of HCC have increased in the United States and Europe in the past decade. Most patients are diagnosed at advanced stages, so there is an urgent need for new systemic therapies [1,2]. To improve the delivery of therapeutic agents to tumor cells in vivo it’s necessary to overcome several problems, such as drug resistance at the tumor level due to physiological barriers (non cellular based mechanism), drug resistance at the cellular level (cellular mechanism), drug distribution, biotransformation and clearance of antic…

Settore CHIM/09 - Farmaceutico Tecnologico Applicativosorafeniblipid nanoparticleshepatocelular carcinoma
researchProduct